Catalent - About the company
Catalent is an acquired company based in Somerset (United States), founded in 2007. It operates as a Provider of development, manufacturing, and packaging solutions for medicines and supplements. Catalent has raised an undisclosed amount in funding from Aisling Capital. The company has 370 active competitors, including 41 funded and 53 that have exited. Its top competitors include companies like Novartis, Biotage and Surrozen.
Company Details
Provider of development, manufacturing, and packaging solutions for medicines and supplements. It offers services for oral dose forms, biologics, and specialty technologies. These services include formulation, bioavailability enhancement, and analytical solutions. The company also provides clinical supply forecasting, packaging, and distribution.
- Website
- www.catalent.com/
- Registered Address
- Somerset, New Jersey
Key Metrics
Founded Year
2007
Location
Somerset, United States
Stage
Acquired
Latest Funding Round
Investors
Ranked
2nd among 370 active competitors
Annual Revenue
$1B+ as on Jun 30, 2024
Employee Count
12,602 as on Mar 31, 2026
Investment & Acquisitions
Exit Details
Acquired by Novo Holdings (Feb 05, 2024)
Legal entities associated with Catalent
Catalent is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Catalent Pharma Solutions, Inc. CIN: 133523163 , United States, Active | Dec 26, 999 | - | 8355 (As on Dec 31, 2024) | - |
CATALENT, INC CIN: 1596783 , United States, Active | Mar 13, 2007 | $1B+ (As on Jun 30, 2024) | 1900 (As on Jun 30, 2023) | - |
CATALENT PHARMA SOLUTIONS CIN: 0800.771.523 , Belgium, Active | Apr 01, 2023 | - | - | - |
Catalent, Inc. CIN: 208737688 , United States, Active | $1 - $1M (As on May 31, 2019) | - | - |
Catalent's acquisition details
Catalent got acquired by Novo Holdings on Feb 05, 2024 at an acquisition amount of $*****.
Click here to take a look at Catalent's acquisition in detail
Sign up to download Catalent's company profile
Catalent's funding and investors
Catalent has raised funding over 4 rounds. Its first funding round was on 2007. Its latest funding round was a Grant (prize money) round on Oct 01, 2020 for $*****. 1 investor participated in its latest round. Catalent has 6 institutional investors.
Here is the list of recent funding rounds of Catalent:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 01, 2020 | 9446691 | Grant (prize money) | 9483680 | 2410988 | 2916572 | 3305225 |
Feb 03, 2020 | 9100136 | Conventional Debt | 8448143 | 7524010 | 5052040 | |
May 04, 2015 | 3694378 | Grant (prize money) | 8130182 | 4582087 | 2708532 |
View details of Catalent's funding rounds and investors
Catalent's founders and board of directors
Founder? Claim ProfileCatalent's employee count trend
Catalent has 12,602 employees as of Mar 26. Here is Catalent's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Catalent's Competitors and alternates
Top competitors of Catalent include Novartis, Biotage and Surrozen. Here is the list of Top 10 competitors of Catalent, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 71/100 | |
2nd | Catalent 2007, Somerset (United States), Acquired | Provider of development, manufacturing, and packaging solutions for medicines and supplements | - | 68/100 | |
3rd | Organic synthesis, analytical, and peptide chemistry services for drug discovery and development | - | 63/100 | ||
4th | Surrozen 2016, San Francisco (United States), Public | Pioneering targeted regenerative antibodies to repair tissue and restore organ function | $133M | 59/100 | |
5th | BioFactura 2004, Frederick (United States), Series B | Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs | $7.8M | 56/100 | |
6th | Biofortuna 2008, Birkenhead (United Kingdom), Series A | Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services | $21.6M | 55/100 | |
7th | Acclinate 2020, Birmingham (United States), Series A | Provider of clinical trial services to biopharma sector | $15.5M | 55/100 | |
8th | Stelis Biosource 2012, Bengaluru (India), Series C | CDMO providing solutions for end-to-end biopharmaceutical manufacturing needs | $195M | 53/100 | |
9th | AmplifyBio 2021, Hilliard (United States), Deadpooled | Provider of contract research, development, and manufacturing services for biologic drugs | $230M | 53/100 | |
10th | Curia 1991, Albany (United States), Acquired | Provider of drug research & development, testing, and consulting services | - | 53/100 |
Looking for more details on Catalent's competitors? Click here to see the top ones
Catalent's Investments and acquisitions
Catalent has made 1 investments in companies including Redwood Bioscience. Catalent has also acquired 16 companies including Metrics Contract Services and VMIC.Here is the list of investments & acquisitions:
Filter this list
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Aug 09, 2022 | Acquisition | 1994 | Greenville (United States) | |
Apr 06, 2022 | Acquisition | 2018 | Oxford (United Kingdom) | |
Aug 30, 2021 | Acquisition | 2009 | Plano (United States) |
See all acquisitions by Catalent
Reports related to Catalent
Here is the latest report on Catalent's geography:
News related to Catalent
Media has covered Catalent for a total of 24 events in the last 1 year, 13 of them have been about company updates and 6 about partnerships.
•
Catalent, Nanoscope Expand Gene Therapy Partnership for MCO-010 Commercial SupplyContract Pharma•Jul 07, 2026•Nanoscope Therapeutics, Catalent
•
Codis Acquires Catalent's Nottingham Site, Enhancing European Spray Drying CapabilitiesPresse Portal•Jul 06, 2026•Catalent, Codis
•
•
Novo's Catalent site in Indiana faces FDA scrutiny over contamination issuesEndpoints•Jun 04, 2026•New Nordic, Catalent
•
Elpida Therapeutics, Catalent Partner for Late-Phase AAV ManufacturingContract Pharma•May 13, 2026•Elpida Therapeutics, Catalent
•
Cartherics and Catalent Expand Commercial License AgreementBusiness Wire•Apr 09, 2026•Cartherics, Catalent
•
•
Cell and Gene Therapy Manufacturing Market Report Forecasts Significant GrowthPR Newswire•Mar 09, 2026•Soterbio, Cellipont, Credence Research Europe, Merck and 6 others
•
Biopharmaceutical CMO Market to Reach USD 76.20 Billion by 2035GlobeNewswire•Feb 24, 2026•Snsinsider, Lonza, Samsung BioLogics, Catalent
•
Oral Solid Dosage Contract Manufacturing Market to Reach USD 60.23 Billion by 2033GlobeNewswire•Feb 19, 2026•Lonza, Thermo Fisher Scientific, Catalent
Are you a Founder ?
FAQs about Catalent
Explore our recently published companies
- Fabric - San Francisco based, 2022 founded, Funding Raised company
- Ambit Equity - Munich based, 2021 founded, Unfunded company
- A Malgam Technologies - Quebec City based, 2016 founded, Funding Raised company
- Billbo - Visakhapatnam based, Unfunded company
- Sooq Al Thahab - Manama based, 2022 founded, Funding Raised company
- Second Ocean - South Korea based, 2025 founded, Funding Raised company